Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

21.07B

Market cap21.07B

Price-Earnings ratio

13.71

Price-Earnings ratio13.71

Dividend yield

—

Dividend yield—

Average volume

1.72M

Average volume1.72M

High today

$147.23

High today$147.23

Low today

$140.58

Low today$140.58

Open price

$144.00

Open price$144.00

Volume

1.94M

Volume1.94M

52 Week high

$204.18

52 Week high$204.18

52 Week low

$110.04

52 Week low$110.04

BIIB News

Simply Wall St 3d

The Bull Case For Biogen Could Change Following New Zorevunersen and BIIB142 Pipeline Milestones

In recent days, Stoke Therapeutics and Biogen announced new long-term clinical data supporting the efficacy and safety profile of zorevunersen for Dravet syndro...

Analyst ratings

53%

of 34 ratings

Buy

47.1%

Hold

52.9%

Sell

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.